Inventor · disambiguated record
Taha Merghoub
Also filed as: MERGHOUB TAHA
43 granted patents·32 pending applications·189 citations·filing 2015–2025
98Inventor score
Files withAGENUS INC41MEMORIAL SLOAN KETTERING CANCER CENTER32ALPHAVAX INC1ICAHN SCHOOL MED MOUNT SINAI1
Top patents by PatentIndex Score
75 records- 0197US10912831B1Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Feb 9, 2021·6 cites·26 claims
- 0297US10836830B2Antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Nov 17, 2020·12 cites·45 claims
- 0396US11638755B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted May 2, 2023·4 cites·20 claims
- 0496US10736962B2Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2017·Granted Aug 11, 2020·15 cites·22 claims
- 0596US10626181B2Nucleic acids encoding anti-OX40 antibodiesAGENUS INC·Filed 2019·Granted Apr 21, 2020·7 cites·35 claims
- 0696US10280226B2Anti-GITR antibodies and methods of use thereofAGENUS INC·Filed 2018·Granted May 7, 2019·17 cites·30 claims
- 0796US10155818B2Anti-GITR antibodies and methods of use thereofAGENUS INC·Filed 2015·Granted Dec 18, 2018·17 cites·4 claims
- 0895US12036279B2Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2022·Granted Jul 16, 2024·2 cites·8 claims
- 0995US11986503B2Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapyMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2022·Granted May 21, 2024·2 cites·14 claims
- 1095US10259882B2Anti-OX40 antibodiesAGENUS INC·Filed 2016·Granted Apr 16, 2019·16 cites·47 claims
- 1194US11285209B2Recombinant MVA or MVAΔE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2020·Granted Mar 29, 2022·3 cites·10 claims
- 1294US11253560B2Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2020·Granted Feb 22, 2022·3 cites·19 claims
- 1394US10639366B2Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2016·Granted May 5, 2020·10 cites·16 claims
- 1494US10548930B2Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2016·Granted Feb 4, 2020·15 cites·18 claims
- 1594US10144779B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2016·Granted Dec 4, 2018·12 cites·92 claims
- 1693US11541087B2Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapyMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2020·Granted Jan 3, 2023·2 cites·12 claims
- 1793US11013802B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2017·Granted May 25, 2021·5 cites·21 claims
- 1893US10512662B2Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapyMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2017·Granted Dec 24, 2019·6 cites·20 claims
- 1992US11267889B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Mar 8, 2022·2 cites·26 claims
- 2092US10479833B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2018·Granted Nov 19, 2019·8 cites·34 claims
- 2189US11345755B2Anti-PD-1 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted May 31, 2022·2 cites·25 claims
- 2288US10800849B2Anti-GITR antibodies and methods of use thereofAGENUS INC·Filed 2018·Granted Oct 13, 2020·2 cites·26 claims
- 2387US10765711B2Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human FLT3L or GM-CSF for cancer immunotherapyMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2019·Granted Sep 8, 2020·2 cites·19 claims
- 2487US10577426B2Anti-GITR antibodies and methods of use thereofAGENUS INC·Filed 2018·Granted Mar 3, 2020·3 cites·21 claims
- 2586US10323091B2Anti-PD-1 antibodies and methods of use thereofAGENUS INC·Filed 2016·Granted Jun 18, 2019·5 cites·94 claims
- 2685US12246066B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2023·Granted Mar 11, 2025·0 cites·19 claims
- 2785US11472883B2Methods of administering anti-OX40 antibodiesAGENUS INC·Filed 2020·Granted Oct 18, 2022·1 cites·15 claims
- 2885US11332536B2Vectors comprising nucleic acids encoding anti-OX40 antibodiesAGENUS INC·Filed 2020·Granted May 17, 2022·1 cites·22 claims
- 2984US11993653B2Antibodies and methods of use thereofAGENUS INC·Filed 2019·Granted May 28, 2024·2 cites·19 claims
- 3084US11447557B2Antibodies and methods of use thereofAGENUS INC·Filed 2016·Granted Sep 20, 2022·3 cites·46 claims
- 3184US11136404B2Anti-OX40 antibodiesAGENUS INC·Filed 2019·Granted Oct 5, 2021·1 cites·64 claims
- 3284US10829559B2Anti-GITR antibodies and methods of use thereofAGENUS INC·Filed 2019·Granted Nov 10, 2020·1 cites·8 claims
- 3384US2023167186A1Methods of administering anti-ox40 antibodiesAGENUS INC·Filed 2022·Application pending·0 cites
- 3484US2023108348A1Methods of administering anti-ox40 antibodiesAGENUS INC·Filed 2022·Application pending·0 cites
- 3584US2025177518A1Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2024·Application pending·0 cites
- 3682US2023039577A1Anti-gitr antibodies and methods of use thereofAGENUS INC·Filed 2022·Application pending·0 cites
- 3780US11359028B2Anti-OX40 antibodies and anti-GITR antibodiesAGENUS INC·Filed 2019·Granted Jun 14, 2022·1 cites·16 claims
- 3880US2023406946A1Antibodies and methods of use thereofAGENUS INC·Filed 2022·Application pending·0 cites
- 3980US2023399413A1Antibodies and methods of use thereofAGENUS INC·Filed 2022·Application pending·0 cites
- 4079US12492257B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2022·Granted Dec 9, 2025·0 cites·20 claims
- 4179US12397029B2Use of MVA or MVADELTAE3L as immunotherapeutic agents against solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2022·Granted Aug 26, 2025·0 cites·13 claims
- 4279US2022098316A1Anti-ox40 antibodies and methods of use thereofAGENUS INC·Filed 2021·Application pending·0 cites
- 4376US2022372149A1Anti-pd-1 antibodies and methods of use thereofAGENUS INC·Filed 2022·Application pending·0 cites
- 4475US11897962B2Anti-GITR antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Feb 13, 2024·0 cites·11 claims
- 4575US11884939B2Vaccinia virus mutants useful for cancer immunotherapyMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2021·Granted Jan 30, 2024·0 cites·16 claims
- 4675US2024239910A1Bi-specific activators for tumor therapyMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2023·Application pending·0 cites
- 4775US2025360209A1Anti-ctla-4 antibodies and methods of use thereofAGENUS INC·Filed 2025·Application pending·0 cites
- 4873US11401335B2Anti-GITR antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Aug 2, 2022·0 cites·16 claims
- 4973US2022389107A1Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereofAGENUS INC·Filed 2022·Application pending·0 cites
- 5073US2022380479A1Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereofAGENUS INC·Filed 2022·Application pending·0 cites
Showing the top 50 of 75 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Taha Merghoub files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →